Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985319 | 0.93 | EPHX2 (0.42) | EPHX2TSHRP2RX7ALDH1A1LMNA | |
| SCHEMBL4986232 | 0.89 | EPHX2 (0.45) | EPHX2TSHRP2RX7ALDH1A1LMNA | |
| SCHEMBL4985490 | 0.89 | P2RX7 (0.48) | EPHX2MEN1KMT2ATSHRP2RX7 | |
| SCHEMBL4989379 | 0.88 | P2RX7 (0.42) | EPHX2MEN1KMT2ATSHRP2RX7 | |
| SCHEMBL4988113 | 0.87 | P2RX7 (0.50) | MEN1KMT2ATSHRP2RX7ALDH1A1 | |
| SCHEMBL4983853 | 0.87 | TNF (0.42) | EPHX2TSHRP2RX7ALDH1A1LMNA | |
| SCHEMBL4982482 | 0.87 | P2RX7 (0.41) | EPHX2TSHRP2RX7ALDH1A1LMNA | |
| SCHEMBL4992282 | 0.87 | ALDH1A1 (0.40) | EPHX2TSHRP2RX7ALDH1A1LMNA | |
| SCHEMBL4982547 | 0.87 | TSHR (0.43) | MEN1KMT2ATSHRP2RX7ALDH1A1 | |
| SCHEMBL4982679 | 0.87 | TSHR (0.43) | EPHX2TSHRP2RX7ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | claimed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | PARK7, UACA, PTGER4 | EPHX2 437/4885MEN1 4084/4885RAB9A 118/4885 |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | EPHX2 569/4885MEN1 4853/4885RAB9A 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.